|Back to main|
BSD, Synapse in MicroThermX Tie-up - Analyst Blog
Cancer treatment systems maker BSD Medical ( BSDM ) has forged a definitive agreement with Synapse Medical for the distribution of its MicroThermX Microwave Ablation products in Ireland and Northern Ireland.
Synapse Medical, a subsidiary of Ireland-based SISK Healthcare, is a leading distributor of medical devices in Ireland and Northern Ireland and is associated with a number of top devices makers. The entity sells medical products to the same physicians and market aimed for MicroThermX.
Synapse has a rich history of bringing new technology to the Irish medical markets. It has a dedicated sales force specialized in marketing products for the interventional radiology/oncology market, the target area for BSD Medical's ablation products. Synapse has already initiated orders for the MicroThermX system.
BSD Medical introduced the innovative MicroThermX system in the U.S. in December 2010. Subsequently, the Utah-based company successfully rolled out its first MicroThermX system in Europe in January 2011.
The MicroThermX system is a transportable, cutting-edge proprietary product, which includes a microwave generator, single-use antennas and a temperature monitoring mechanism. It is capable of generating significant levels of power with one generator. Its usage helps approach larger and more uniform areas of ablation during a procedure.
The MicroThermX system leverages BSD Medical's proprietary synchronous phased array technology to deliver precision-guided microwave energy to ablate soft tissues using a single-patient-use disposable antenna.
The minimally-invasive MicroThermX system has been developed to provide treatments as a stand-alone therapy and has applications in open surgical and percutaneous (via needle-puncture of the skin) ablation procedures. As such, it can be used by both surgeons and interventional radiologists.
BSD Medical competes with established players like Boston Scientific ( BSX ) and Angiodynamics ( ANGO ) in the thermal ablation market. The global market potential for soft tissue ablation has been estimated to exceed $2.3 billion, offering a significant opportunity for BSD Medical.
ANGIODYNAMICS ( ANGO ): Free Stock Analysis Report
BOSTON SCIENTIF ( BSX ): Free Stock Analysis Report
Zacks Investment Research